Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.55 USD
Change Today +0.0081 / 1.50%
Volume 165.1K
APPY On Other Exchanges
Symbol
Exchange
APPY is not on other exchanges.
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

venaxis inc (APPY) Snapshot

Open
$0.55
Previous Close
$0.54
Day High
$0.55
Day Low
$0.53
52 Week High
07/2/14 - $2.53
52 Week Low
02/3/15 - $0.40
Market Cap
17.0M
Average Volume 10 Days
175.4K
EPS TTM
$-0.29
Shares Outstanding
31.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VENAXIS INC (APPY)

Related News

No related news articles were found.

venaxis inc (APPY) Related Businessweek News

No Related Businessweek News Found

venaxis inc (APPY) Details

Venaxis, Inc., an in vitro diagnostic company, engages in the development and commercialization of products for unmet diagnostic and therapeutic needs. The company’s research, development, and commercial activities primarily focus on a human acute appendicitis blood-based test. Its lead product candidate includes APPY1, a novel blood-based diagnostic test designed to aid in the evaluation of patients for acute appendicitis. Venaxis, Inc., through its license agreement with Washington University in St. Louis, develops, markets, sells, distributes, imports, and exports luteinizing hormone and/or follicle-stimulating hormone products for bovine, equine, and swine animals. The company was formerly known as AspenBio Pharma, Inc. and changed its name to Venaxis, Inc. in December 2012. Venaxis, Inc. was founded in 2000 and is based in Castle Rock, Colorado.

24 Employees
Last Reported Date: 03/30/15
Founded in 2000

venaxis inc (APPY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $375.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $254.9K
Commercial Consultant
Total Annual Compensation: $260.6K
Compensation as of Fiscal Year 2014.

venaxis inc (APPY) Key Developments

John H. Landon to Retire as Director of Venaxis, Inc., Effective June 1, 2015

Venaxis, Inc. announced that at the Board meeting held on May 6, 2015, John H. Landon, a director since December 2008, announced his intention to retire from his Board service effective June 1, 2015.

Venaxis, Inc., Board Meeting, May 06, 2015

Venaxis, Inc., Board Meeting, May 06, 2015. Agenda: To consider the retirement of directors.

Venaxis, Inc. - Special Call

To discuss FDA updates, European commercial activities, product development and other corporate matters

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APPY:US $0.55 USD +0.0081

APPY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for APPY.
View Industry Companies
 

Industry Analysis

APPY

Industry Average

Valuation APPY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 132.1x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENAXIS INC, please visit www.venaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.